– USA, CA – Biosplice Therapeutics, Inc., a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for major diseases, today announced the addition of Troy Cox, Susannah Gray, and Karen McGinnis to its Board as Independent Directors.
“We are honored to have this caliber of experience and leadership join our new board at Biosplice,” said Founder and Executive Chairman, Dr. Osman Kibar . “Ms. Gray, Ms. McGinnis, and Mr. Cox bring invaluable insight to our company as we continue the buildout of our alternative splicing platform and navigate the final stages of clinical development for our lead osteoarthritis drug candidate, lorecivivint, and continue to develop our promising oncology and neurology pipelines.”
About Troy Cox
Troy Cox led Foundation Medicine (NASDAQ: FMI), as President and CEO, through the acquisition by Roche for $5.3 billion in 2018. Before Foundation Medicine, he served as SVP and Officer at Genentech, where he led US BioOncology for a period of unprecedented growth to over $12 billion while accountable to help steer the Roche Genentech R&D portfolio. Before Genentech, Mr. Cox held executive and senior roles, including President UCB BioPharmaceuticals, SVP Sanofi-Aventis, and diverse foundational roles at Schering-Plough. He also currently serves as a director of Zymeworks, Inc. (NYSE: ZYME), Sophia Genetics, LetsGetChecked, CM Life Sciences II (NASDAQ: CMIIU), and MassBio.
About Susannah Gray
Susannah Gray brings more than 30 years of biopharmaceutical experience, specifically in corporate finance and capital markets roles, most recently serving as EVP, Finance & Strategy of Royalty Pharma Management, LLC. Ms. Gray also spent 14 years as EVP and CFO of Royalty Pharma before retiring in 2019. Before joining Royalty Pharma, she had a 14-year career in banking, working in various capacities within high yield and structured finance departments of Chase Securities, Merrill Lynch, and CIBC World Markets. Ms. Gray also serves as a director of Maravai LifeSciences (NASDAQ: MRVI) and 4D Molecular Therapeutics (NASDAQ: FDMT).
About Karen McGinnis
Karen McGinnis has over 20 years of experience in executive operational and finance roles at international public companies. She most recently served as VP & Chief Accounting Officer of Illumina, Inc. (NASDAQ: ILMN), a leader in sequencing- and array-based solutions for genetic and genomic analysis. Earlier in her career, Ms. McGinnis served as Director, President, and CEO, and previously CFO, of Mad Catz Interactive, Inc. (OTC: MCZAF), a global provider of innovative interactive entertainment products. Before joining Mad Catz, Ms. McGinnis served as Chief Accounting Officer of Cymer, Inc., a leading supplier to the semiconductor industry and, previously, Chief Accounting Officer for Insight Enterprises, Inc. Ms. McGinnis also currently serves as a director of Alphatec Holdings, Inc. (NASDAQ: ATEC) and AbSci, Inc.
About Biosplice Therapeutics
Biosplice Therapeutics is developing first-in-class, small-molecule therapeutics based on pioneering science of alternative pre-mRNA splicing. Stemming from foundational discoveries in Wnt pathway modulation, Biosplice has elucidated novel biology linking CLK/DYRK kinases to the therapeutic regulation of alternative splicing. Alternative splicing is an essential biological mechanism that regulates the diversification of proteins in a cell, which, in turn, determines cell type and function. Biosplice’s target class governs the selection of tissue-specific mRNA splice sites, making them attractive, druggable targets within the cellular “command and control” center.
Biosplice’s drugs in clinical development include lorecivivint for osteoarthritis (in Phase 3), cirtuvivint for numerous cancers, and a broad pipeline that ranges from Alzheimer’s disease to other degenerative conditions.
For more, visit https://www.biosplice.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.